Patrik Andersson

Patrik Andersson

Auto-generated profile, based on publicly available information

Patrik Andersson

AMRA Medical AB

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

24 November 2022 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
ETE. Thunell
E. Thunell
MPM.G. Peter
M.G. Peter
VLVincent Lenoir
Vincent Lenoir
PAP. Andersson
P. Andersson
BLBasile N. Landis
Basile N. Landis
JLJohan Lundström
Johan Lundström
BACKGROUND AND PURPOSE: Reduced olfactory function is the symptom with the highest prevalence in coronavirus disease 2019 (COVID-19) with nearly 70% of infected individuals experiencing partial or total loss of their sense of smell at some point during the disease. The exact cause is not known, but beyond peripheral damage, studies have demonstrated insults to both the olfactory bulb and central olfactory brain areas. However, these studies often lack both baseline pre-COVID-19 assessments and control groups, and the effects could, therefore, simply reflect pre-existing risk factors. MATERIALS AND METHODS: Shortly before the COVID-19 outbreak, we completed an olfactory-focused study, which included structural MR brain images and a full clinical olfactory test. Opportunistically, we invited participants back 1 year later, including 9 participants who had experienced mild-to-moderate COVID-19 (C19+) and 12 who had not (C19−), creating a natural pre-post experiment with a control group. RESULTS: Despite C19+ participants reporting subjective olfactory dysfunction, few showed signs of objectively altered function. Critically, all except 1 individual in the C19+ group had reduced olfactory bulb volume (average reduction, 14.3%), but this did not amount to a significant statistical difference compared with the control group (2.3%) using inference statistics. We found no morphologic differences in olfactory brain areas but stronger functional connectivity between olfactory brain areas in the C19+ group at the postmeasure. CONCLUSIONS: Our data suggest that COVID-19 might cause long-term reduction in olfactory bulb volume and altered functional connectivity but with no discernible morphologic differences in cerebral olfactory regions.

24 September 2024 in Obesity
Verified
Journal Article
Closed access
PAPatrik Andersson
Patrik Andersson
JLJennifer Linge
Jennifer Linge
TGTiril P. Gurholt
Tiril P. Gurholt
ISIda E. Sønderby
Ida E. Sønderby
GHGuy Hindley
Guy Hindley
OLOlof Dahlqvist Leinhard
Olof Dahlqvist Leinhard

11 December 2025 in medRxiv
Verified
Preprint
Open access
PDF file
DADaniel Edvard Askeland-Gjerde
Daniel Edvard Askeland-Gjerde
LWLars T. Westlye
Lars T. Westlye
DADag Alnaes
Dag Alnaes
PAPatrik J. Andersson
Patrik J. Andersson
DBDani Beck
Dani Beck
TGTiril P. Gurholt
Tiril P. Gurholt
Objective: Bipolar (BD) and psychotic disorders (PD) are severe mental disorders (SMDs) associated with higher cardiometabolic disease burden. Prior studies of body composition in SMDs are inconclusive. Magnetic resonance imaging (MRI) offers detailed insights into body composition and may improve our understanding of cardiometabolic disease risk in patients with SMDs. Methods: We derived body composition measures from MRI of patients with BD (n=36, 63.9% females, mean age=36.6±10.9 years), PD (n=27, 33.3% females, mean age=31.7±8.9 years), and controls (n=251, 78.8% females, mean age=40.7±12.1 years). Using linear models we tested for case-control differences in body mass index (BMI) and body composition in all patients and split by diagnostic group (BD and PD), accounting for age, sex, and scanner, and subsequently adding BMI. Next, we tested for age- and sex-adjusted associations between body composition and antipsychotic dose in patients. Results: Analyses showed significantly higher BMI (BD: Cohen’s d=0.70; PD: d=0.65), abdominal subcutaneous fat (BD: d=0.78; PD: d=0.71), visceral fat (BD: d=0.76; PD=0.68), liver fat (BD: d=0.53; PD: n.s.), and thigh muscle fat infiltration (BD: d=0.80; PD: d=0.87) in cases compared to controls. When accounting for BMI, muscle fat infiltration remained significantly higher (BD: d=0.54; PD: d=0.68) and thigh muscle volume was lower (BD: d=-0.65; PD: d=-0.63). There were no significant associations of antipsychotic dose with BMI or body composition. Conclusions: The observed case-control differences suggest that individuals with BD and PD, at the group level, exhibit higher regional fat accumulation and lower muscle volume, possibly contributing to the heightened risk for cardiometabolic comorbidity in SMDs.